Axelar attends BIO Investor Forum in San Francisco, USA

Axelar AB will attend the BIO Investor Forum in San Francisco, USA on October 17-18, 2017 to meet with potential partners and investors. The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. Axelar’s participation marks the kick-off the fundraising efforts to fund the next phase of clinical development focused now that Axelar has received orphan drug designation for AXL1717 for the treatment of glioma. 

About AXL1717 (picropodophyllin)

AXL1717 is an orally bioavailable small molecule with dual mechanisms of action, which has been shown to pass through the blood-brain barrier. AXL1717 targets the IGF-1R signaling pathway but does not bind the IGF-1R. AXL1717 has also been shown to yield cell cycle arrest in mitosis, due to indirect effects on microtubule dynamics, making it a unique anti-cancer drug.

About Axelar AB

Axelar is a Swedish drug development company developing targeted oral anti-cancer therapies for indications where there are significant unmet medical needs. The company was founded based on research performed at Karolinska Institutet, Stockholm and the discovery of a group of compounds that target the IGF-1 receptor signaling pathway without affecting signaling from the closely related insulin receptor.

For additional information about Axelar, please visit

Go back